Our survey focused on key areas related to the implementation and adoption of digital technologies in biopharma R&D: strategy, value, progress, and barriers to adoption. Although we validated that some progress is being made, we did find a greater-than-anticipated gap between the expected value of digital in R&D and actions being taken to realize that value. Our report offers steps to help companies harness digital as a strategic enabler.
Biopharmaceutical companies are at a crossroads
While nearly three quarters of respondents believe digital will drive success in achieving key strategic R&D imperatives, just 36% say they're adopting digital as a key strategy. We believe that companies will see the benefits of their investments in digital when they address barriers including risk aversion, cultural and operational impediments and move from silos to scale.
What’s the right path to digitalization?
It’s clear from our survey results that the desire exists to further adopt digital technologies—a desire that we expect is even greater today given the need to accelerate clinical development. Our observations and experience working with other industries prove that change will happen. What we don't know is the pace, who will set the tempo and who will ultimately lead.